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ABSTRACT
Background: The duplex mutation primers offer many advantages over other multi-
labeled probes for real-time detection of amplification products.
Objectives: To develop and validate a novel real-time PCR for quantification of HCV RNA 
based on the duplex mutation primers technology.
Materials and Methods: The duplex mutation primers were selected in the highly con-
servative 5' non-coding region (5'NCR) of the HCV RNA. The assay was validated with 
the Viral Quality Control panel, which also includes Chinese HCV RNA standards.
Results: The detection limit was 57 IU/mL, and a good linear correlation in the range 
of 102–108 IU/mL was revealed (r 2 = 0.999) with the novel method. This assay has a dy-
namic range of at least 8 log10 without the need for specimen dilution, good clinical 
intra- and inter-run precision, and excellent correlation with a commercially available 
assay(r 2 = 0.95).
Conclusions: The high sensitivity, wide linear range, and good reproducibility, com-
bined with low cost, make this novel quantitative HCV real-time PCR assay particularly 
well suited for application to clinical and epidemiological studies.
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1. Background
Quantitative  hepatitis  C  virus  (HCV)  RNA 
determinations  are  currently  the  standard  of  care  for 
diagnosis  of  acute  and  chronic  HCV  infections  and 
monitoring for therapeutic efficacy. Several home-made 
and  commercial  real-time  PCR  assays  have  been  used 
to quantify the level of HCV RNA in serum samples (1-3). 
The nonspecific dsDNA binding dyes methods are prone 
to  “false  positives”  in  that  undesired  dsDNA  such  as 
primer dimers and other spurious amplicons can bind 
dyes  to  produce  fluorescence  (4).  Well-known  specific 
multi-labeled  FRET  probes  examples  include  TaqMan 
(5),  molecular  beacons  (6),  scorpion  primers  (7),  and 
amplifluor (8). The synthesis and purification of these 
multi-labeled probes are often either trivial or expensive 
relative to the pair of fluorophore and the quencher in the 
same  oligonucleotide.  Although  hybridization  probes 
(9), displacing probes (10) and Q-PNA primers (11) have Hepat Mon. 2011;11(7):519-524
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some  advantages  over  multi-labeled  probes.  However, 
both hybridization probes and displacing probes need 
the  phosphatation  to  block  the  amplification,  are  not 
real single-labeled probes and the costs are increased. 
We reported a new method based on duplex mutation 
primers, in which a primer with a fluorophore is attached 
at its 5’-end, and a complementary oligonucleotide with 
a single-base mismatched is labeled by a quencher at 3’-
end (12). Incorporation of the fluorophore primer into a 
double stranded amplicon causes the physical separation 
of the fluorophore and quencher moieties, and produces 
an increase of the fluorescence signal, which is the direct 
indicator  of  the  template  concentration.  The  duplex 
mutation primers are much more specific than double-
strand  DNA  dyes  like  SYBR  Green  I,  etc.  Unlike  other 
probes (5-8), duplex mutation primers do not require the 
double labeled synthesis of fluorophore and quencher 
on the same molecule, which makes the synthesis of the 
FRET probe less costly and design more convenient. 
2. Objectives
The purpose of this study was to report the development 
of  a  quantitative  real-time  PCR  HCV  RNA  assay  using 
duplex  mutation  primers  technology.  We  evaluated 
the sensitivity, specificity and efficacy of this assay and 
its  usefulness  for  the  diagnosis  of  HCV  infection.  The 
correlation between results with this assay and with the 
TaqMan assay was investigated.
3. Materials and Methods
3.1. Patient samples
The clinical samples included 92 sera collected from 
patients with an acute or chronic HCV infection. To test 
for specificity, we used samples anonymously obtained 
from each of the following groups: apparently healthy 
volunteers of our hospital (n = 60), HBV-monoinfected 
patients (n = 45), and HAV-monoinfected patients (n = 
5). All healthy volunteers had normal serum ALT levels 
and were negative for antibodies to HCV by ELISA. For all 
samples, sera was separated from whole blood, aliquoted, 
and stored at -20°C until it was further processed.
3.2. Viruses for analytical studies
The  Chinese  National  standard  for  HCV,  which  has 
an  assigned  concentration  of  1.25×106  IU/mL,  was 
serially  diluted  in  negative  human  plasma  to  a  final 
concentration  ranging  from  1×106  to  1×102  IU/mL,  and 
were used as reference standards for each real-time PCR 
run. Analytical verification studies (measurable range, 
LOD, and precision) were performed with a commercial 
panel  of  clinical  specimens  containing  HCV  Gt  1a,  Gt 
2b,  and  Gt  3a  viruses  (DaAn,  Ltd.  Guangzhou,  China). 
For  a  standardized  evaluation,  we  obtained  a  Chinese 
National  reference  viral  quality  control  (VQC)  plasma 
preparation  panel  containing  well-characterized  HCV 
RNA levels. These samples were tested extensively and 
contain HCV RNA levels ranging from no HCV RNA to 107 
HCV molecules per mL.
3.3. Nucleic acid extraction
Total  RNA  was  extracted  from  200  µL  of  serum 
with  a  Trizol  kit  (Invitrogen,  USA)  according  to  the 
manufacturer’s instructions. After the extraction by the 
Trizol kit, the total amount of extracted nucleic acids was 
solved in 100 µL.
3.4. Reverse transcription
A total volume of 25 µL of reverse transcription reaction 
mixture was prepared as follow: 1 µL of random primers 
(0.2 µg/µL, Promega, USA) was added to 5 µL of extracted 
HCV  RNA.  The  mixture  was  denatured  at  70°C  for  5 
minutes and cooled on ice immediately. Then 5 µL of 5× 
reverse transcription buffer, 0.75 µL of RNasin (40 U/µL, 
Promega, USA), 1 µL of M-MLV reverse transcriptase (200 
U/µL, Promega, USA), 1.25 µL of dNTP (10 mM, Promega, 
USA) and 11 µL of RNase-free water were added into the 
reaction tube. The tube was flicked gently and incubated 
for 60 minutes at 37°C. The reaction was terminated at 
95°C for 5 minutes. Reverse transcription products (cDNA) 
were frozen at -20°C until further use. The presence of 
HCV  cDNA  in  these  samples  was  then  analyzed  with 
commercial TaqMan kit (Da’an Ltd., Guangzhou, China) 
and our method.
3.5. Preparation of duplex mutation primers
The  fluorophore  primers  (5’-FAM-
CGACACTCCACCATAGATCAC-3’) and the reverse primers 
(5’- AGGCTGCACGACACTCATAC -3’) were used to amplify 
a  94-bp  fragment  in  the  highly  conservative  5’  non-
coding region (5’NCR) of the HCV RNA. The fluorophore 
primers  were  quenched  by  partly  complementary 
oligonucleotides ( 5’-GTGATCTATGGCGGAGTGTCG-
Dabcyl-3’)  of  a  single-base  mismatched  labeled  with  a 
quencher at 3’-end. All of the primers were selected using 
the primer premier 5.0 software and were synthesized, 
purified and labeled by Takara Ltd. Dalian, China.
Concentration,IU/mL positive, % 
(positive/total replicates, No.)
400 100 (8/8)
200 100 (8/8)
100 100 (8/8)
50 87.5 (7/8)
25 50 (4/8)
12.5 37.5 (3/8)
6.3 12.5 (1/8)
3.1 0
1.6 0
Table 1. Limit of the HCV RNA real-time PCR assayHepat Mon. 2011;11(7):519-524
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3.6. Real-time PCR system
Real-time PCR was performed with a Rotor-Gene 3000 
(Corbett  Robotics,  Australia).  The  total  volume  of  the 
real-time PCR was 20 µL containing 5 µL of cDNA, 4 µL 
duplex  mutation  primers ( 2.0  µM  of  the  fluorophore 
primer,  2.0  µM  of  the  quencher  strand),  4  µL  reverse 
primer (2.0 µM), 2.5 µL each dNTP (1.6 mM, Takara Ltd. 
Dalian, China), 2 µL 10× buffer, 0.2 µL of Taq polymerase 
(5 U, Takara Ltd. Dalian, China) and 1 µL MgCl2 (25 mM, 
Takara Ltd. Dalian, China), adding distilled water to 20 
µL. The cycling parameters were an initial denaturation 
at 94 °C for 5 min, 40 cycles of 93 °C for 15 s, and 48 °C for 
15 s. The signal detection was preformed at 48 °C during 
each cycle. To quantify the starting template in samples, 
the samples were run in along with a standard curve 
generated from 10-fold serially diluted standard serum 
of a known concentration.
3.7. Lower limit of detection
To test for the lower limit of detection, the stock of the 
commercial panel of clinical specimen was diluted with 
sterile water to 400, 200, 100, 50, 25, 12.5, 6.3, 3.1, and 1.6 
IU/mL. Eight replicates of each dilution and two negative 
controls were then tested by our method.
3.8. Linearity
To test the linearity of the quantitative PCR, the stock 
of  the  HCV  reference  standard  at  a  concentration  of 
1.25×106 IU/mL, was diluted stepwise (1:10), and four to six 
replicates were tested per dilution. Furthermore, a high 
concentration plasma sample (as measured by the HCV 
Diagnostic kit) from a patient was diluted stepwise (1:10), 
and two replicates per dilution were tested.
3.9. Precision
To  test  the  inter-run  precision,  four  samples  of  HCV 
RNA from patients with low, medium and high levels of 
viremia as well as one sample from healthy volunteers 
were  aliquoted  and  stored  at - 20 ° C  before  use.  These 
five samples were repeatedly assayed five times in five 
independent experiments. The results of quantitation, 
along  with  standard  deviations  and  coefficients  of 
variation ( CVs),  intra-run  precision  were  determined 
by measuring the amount of HCV RNA in the 5 samples 
mentioned above within one PCR run.
3.10. Correlation between the novel PCR assay and a 
commercially assay
The HCV RNA real-time PCR assay was compared with 
a  commercially  available  TaqMan  assay ( Diagnostic 
kit  for  HCV,  DaAn,  China)  to  determine  its  usefulness 
for a clinical virology laboratory. A total of 202 serum 
specimens  were  tested  by  both  methods.  Samples 
were not tested simultaneously on both platforms but 
were  first  tested  by  the  commercially  available  assay 
and then frozen at -20 °C until RNA extraction and the 
novel  PCR  testing.  Specimens  throughout  the  range 
of  quantification  were  chosen  for  analysis.  Data  were 
logarithmically transformed before analysis.
3.11. Data analysis
Reproducibility  was  estimated  by  computing  CVs. 
The difference of the quantitative results between the 
commercial TaqMan kit and the developed method was 
assessed by the paired-sample Student’s t test or the Sign 
test  when  the  results  were  not  distributed  normally. 
Probit statistics was performed to determine the limit of 
detection of our HCV real-time PCR assay. P < 0.05 were 
considered statistically significant.
                                                 HCV RNA , IU/mL Mean SD CV, %
1 2 3 4 5
Intra-run
1
2
3
4
2.14×102
1.39×103
5.17×104
7.45×107
2.36×102
1.21×103
5.36×104
7.37×107
2.24×102
1.24×103
5.25×104
7.39×107
2.01×102
1.31×103
5.19×104
7.41×107
1.95×102
1.19×103
5.12×104
7.31×107
2.14×102
1.27×103
5.22×104
7.39×107
1.67×101
8.2×101
9.2×102
5.2×105
7.80
6.46
1.76
0.70
Control N a N N N N - - -
Inter-run
1
2
3
4
2.44×102
1.39×103
5.17×104
7.51×107
2.31×102
1.32×103
5.24×104
7.37×107
2.12×102
1.20×103
5.09×104
7.30×107
2.19×102
1.27×103
5.31×104
7.21×107
1.85×102
1.15×103
5.37×104
7.47×107
2.18×102
1.27×103
5.24×104
7.37×107
2.22×101
9.50×101
1.11×103
1.23×105
10.18
7.48
2.12
1.67
Control N N N N N - - -
Table 2. Study of intra and inter-run variability of the HCV RNA real-time PCR assay to determine its precision
a N: negativeHepat Mon. 2011;11(7):519-524
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4. Results
4.1. Real-time PCR detection
The results of real-time PCR analysis of the single copy 
conservative sequence in HCV genome as a function of 
template copy number using our primers are shown in 
Figure 1. A Chinese National standard for HCV dilution 
series of 102–106 IU/mL was amplified in each PCR run. 
The  cycle  threshold ( Ct)  was  automatically  set  by  the 
instrument  software.  The  calibration  curve  of  Ct  vs. 
template  copy  number  showed  linear  regression 
analysis of the best-fit line yielded a good coefficient of 
determination (r 2) of 0.999 (Figure 1). Analysis of reaction 
products by electrophoresis revealed that the correct size 
of the reactions produced amplicons.
4.2. Limit of detection
The samples yielded positive results in 100% of replicate 
reactions at concentrations greater than or equal to 100 
IU/mL.  Below  the  concentration,  the  detection  failure 
rate increased as the concentration decreased (Table 1). 
A clinical sample was quantified by serially diluting the 
stock  solution,  performing  eight  amplifications  with 
the  novel  method,  and  calculating  the  concentration 
from the fraction of negative reactions by application of 
Poisson’s law. A detailed probit analysis indicated that 
the limit of detection (the concentration at which 95% or 
more of the replicates tested gave a positive response) of 
the test was 57 IU/mL.
4.3. Linearity
Linearity  was  confirmed  using  a  patient  sample 
with  high  levels  of  HCV  RNA.  After  various  dilutions, 
the  nucleic  acid  was  extracted  and  the  HCV  RNA  was 
quantified. Linearity was observed from 102 up to 108 IU/
mL in the sample.
4.4. Precision
The  inter-  and  intra-run  variability  were  tested ( see 
Materials and Methods); the results are shown in Table 2. 
4.5. Specificity
To  determine  the  specificity  of  the  real-time  PCR 
detection  assay,  we  used  110  samples  anonymously 
obtained from each of the following groups: apparently 
healthy  volunteers  of  our  hospital ( n  =  60),  HBV-
monoinfected patients (n = 45), and HAV-monoinfected 
patients ( n  =  5).  None  of  the  samples  showed  false- Figure 2. Graph shin correlation of the HCV real-time PCR assay results with 
the new method results for 92 HCV-positive clinical spcimens (numerical 
values e not listed). There was excellent correlation (r 0. 95) between the two 
assays for all samples.
From the left to the right, these nine fluorescent curves from 106 to 102 IU/mL are shown: and the negative control is represented by the horizontal black curve (A). 
Standard curve used to calculate the concentration of HCV RNA in unknown samples. The linear regression coefficient is close to 1 (B).
Figure 1. Fluorescent curves of the standard dilution series
A
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positive reactions in duplicate.
4.6. Comparison between two different quantification 
assays
The  presence  or  quantity  of  HCV  RNA  in  the  sera  of 
the  92  HCV  patients  was  determined  by  our  method 
and  commercial  TaqMan  kit  separately.  There  was  no 
significant  difference  among  the  tested  results  with 
two methods in 92 HCV hepatitis patients (P = 0.723). A 
significant  positive  linear  correlation  was  found ( r  2 = 
0.95, Figure 2).
5. Discussion
Methods for HCV RNA quantitation must be specific, 
sensitive, reproducible, and accurate. Analysis of large 
number  of  samples  requires  a  rapid  and  manageable 
protocol that minimizes as much as possible post-PCR 
manipulations. Endpoint PCR-based techniques for HCV 
RNA have shown a limited dynamic range, usually within 
4 logs, affecting the quantification of moderate to high 
levels of viremia (13). Real-time PCR is designed to quantify 
nucleic acids in the exponential phase of the reaction, 
allowing for a more reliable and precise quantification 
over  a  much  wider  dynamic  range.  Quantitative  tests 
of HCV RNA levels in serum are currently the standard 
of  care  for  the  diagnosis  of  acute  and  chronic  HCV 
infections and monitoring for therapeutic efficacy (14). In 
this study, we described the development and validation 
of a novel quantitative real-time PCR assay that showed 
good performance characteristics in terms of the limit of 
detection, linearity, reproducibility, and specificity. This 
assay has good clinical sensitivity at 57 IU/mL using an 
initial sample volume of only 200 µL, at least an 8 log10 
linear  dynamic  range  without  the  need  for  specimen 
dilution. This linearity was well in line with the linearity 
of  other  assays  performed  on  the  Cobas  TaqMan  HCV 
platform ( 15).  The  low  variability  of  this  assay  makes 
a twofold decrease or increase in the serum HCV RNA 
level  already  significant.  The  mandatory  requirement 
of 100% specificity was achieved, as none of the controls, 
including  healthy  donors  and  patients  infected  with 
HBV or HAV, was tested positive HCV RNA. Nevertheless, 
the number of control samples need to be increased to 
further confirm these findings. The high reproducibility 
and  linearity  of  the  assay  described  proved  to  be 
comparable with one commercially available assay. Our 
method  has  several  advantages  over  the  other  multi-
labeled probes methods; higher specificity: the primers 
are duplex form and cannot hybridize with each other 
at  lower  temperature  than  their  melting  temperature 
that minimizes non-specific annealing in the course of 
amplification.  Higher  sensitivity:  after  primer-target 
hybridization,  the  distance  between  the  fluorophore 
and  the  quencher  changes  from  close  proximity  to 
totally free separation. This property endows them with 
stronger signal than other internal FRET probes. Higher 
cost/efficiency: single-labeled oligonucleotides structure 
makes  the  synthesis  less  costly  and  design  more 
convenient  than  multi-labeled  probes.  In  conclusion, 
a duplex mutation primers real-time PCR system with 
high cost/efficiency, rapid, sensitive and high specificity 
has been developed for the quantitative detection of HCV 
RNA. The assay is suitable to be used for both clinical and 
epidemiological studies.
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